Diagnostic profit in 2024 consistent with estimates. The group is planning further acquisitions

In 2024, the Diagnostics Group had over PLN 223 million of JD net profit, according to estimates – the company said in the report. The group is planning further acquisitions.

In 2024, the group's revenues from contracts with clients increased by 22.8 percent. up to PLN 1,950 million, and after excluding the influence of Covid-19 from 2023 by 23.1 percent. rdr.

“Such a good result was primarily influenced by dynamic organic development, which achieved 20.7 percent, driven by both the increase in the volume of tests performed (14.8 percent) and the increase in the average price of sold tests (7.3 percent)” – it was written.

Recurring EBITDA increased by 32.8 percent rdr. up to PLN 508.7 million in 2024, mainly due to the consistent increase in revenues, which in the control of operating costs allowed to increase the recurring EBITDA2 margin) by 2.0 pp to 26.1 percent.

In turn, net profit increased by 78.4 percent. rdr. up to PLN 232 million, and the net profit falling to the shareholders of the dominant company by 80.9 percent. up to PLN 223 million.

“Behind us is another successful year in which we have developed very good financial results and implemented key investments strengthening our position of the Laboratory Diagnostics Leader. The past year was also a time of subsequent investments in imaging diagnostics and intensive preparations for launching the first clinic of comprehensive diagnostics in Poland, which already operates at Jutrzenki 100 in Warsaw” Swadzba.

“We are convinced that 2025 will bring further development of the diagnostic group and open new possibilities to us, both as part of organic growth and acquisitions,” he added.

Last year, diagnostics opened the imaging diagnostics workshop in Warsaw and Bielsko-Biała and a new gynecological cytology studio in Warsaw. It was pointed out that a special milestone was the completion of the construction of a new headquarters in Łódź, which houses the Central Analytical Laboratory and the largest pathomorphology plant in Poland, enabling the implementation of up to 3 million tests per month.

“The expansion on the imaging diagnostics market is one of the key pillars of our development strategy. In 2024, we realized the acquisitions of diagnostics -teleradiology and Livmed companies, and also increased the shares in the company Diagnostyka Wyckiek, obtaining control over it. These activities significantly strengthened our position in this segment,” said how to swadzieba. “

“At the beginning of April this year, Eurodiagnostic also joined the group. According to our strategy, we are planning further acquisitions in the imaging diagnostics segment” – he added.

It was indicated that in response to the growing awareness of the importance of health prevention, diagnostics develops a new segment of activity – comprehensive diagnostics.

“We are consistently increasing the scale of our business activity, while improving the profitability and EBITDA margins. We are favored by the growing market, more and more public awareness in the field of health prevention and demographic trends, which gives potential to further organic development” – said Vice President Paweł Chytła.

“We maintain an attractive growth trajectory, which confirms the effectiveness of our development strategy. High conversion of free cash flow to EBITDA at 85.3 percent and strong cash flows give us financial comfort and flexibility necessary for further development, both in the organic dimension and acquisitions” – he added.

The Supervisory Board of Diagnostics has positively approved the Management Board's recommendation regarding the distribution of profit for 2024, including the purpose of PLN 111.7 million for dividend payment for shareholders, which corresponds to a dividend of PLN 3.31 per share. (PAP Biznes)

alk/ ana/